ArticleEcancermedicalscience2014
Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.
Article in Ecancermedicalscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles.International journal of molecular sciences · 2023Article
- Review
- Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview.OncoTargets and therapy · 2021Review
- Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort.Frontiers in pharmacology · 2021Article
- Review
- Third-line sunitinib treatment in aCancer biology & therapy · 2020Review
- Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV.Journal of gastrointestinal oncology · 2019Article
- Going to extremes: determinants of extraordinary response and survival in patients with cancer.Nature reviews. Cancer · 2019Review
- Article
- Stochastic phenotype switching leads to intratumor heterogeneity in human liver cancer.Hepatology (Baltimore, Md.) · 2018Article
- Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors.Oncotarget · 2018Article
- Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Medicine · 2018Article
- The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Therapeutic advances in gastroenterology · 2017Review
- Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.Journal of gastrointestinal oncology · 2017Article
- Impressive response to dualJournal of gastrointestinal oncology · 2016Article
- Molecular profiling of biliary tract cancer: a target rich disease.Journal of gastrointestinal oncology · 2016Review
- KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.Cureus · 2016Article
- Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies.Hepatic oncology · 2015Review
- Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.Cancer discovery · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is the case of a 47-year-old woman diagnosed with chemotherapy and radiation-refractory BRAF V600E mutant, poorly differentiated intrahepatic cholangiocarcinoma (ICC), with multiple metastatic lesions within the liver, lungs, pleura, and bone, stage IV. Discussion of her malignancy's next-generation sequencing genomic information at a multidisciplinary molecular tumour board took place. The patient was considered a suitable candidate for dual BRAF and MEK inhibition, with the intent to prolong her survival and optimize the quality of life. We report her excellent tolerance and exceptional response to dual therapy with dabrafenib and trametinib, including symptomatic and sustained near-complete radiological improvement. We also briefly review the current knowledge of the genomics of cholangiocarcinoma with a focus on BRAF mutations, and make a point of the importance of the establishment of a molecular tumour board for personalized genomic medicine approaches. To our knowledge, this is the first reported case of the use of personalized genomic information for the successful management of a patient with ICC, and it is also the first description of dual BRAF and MEK targeted therapy in this malignancy, leading to what is considered an exceptional response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.